☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - October 2013

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Bimatoprost / Timolol preservative-free eye-drops (Ganfort® Unit Dose) have been accepted for restricted use in the treatment of open-angle glaucoma or ocular hypertension. The restriction limits use to patients who have proven sensitivity to preservatives.

Nalmefene (Selincro®) has been accepted for use in the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification. It is recommended that this medication only be prescribed in conjunction with continuous psychosocial support and if the drinking risk level remains high two weeks after initial assessment.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - October 2013' by emailShare 'SMC Update - October 2013' on FacebookShare 'SMC Update - October 2013' on TwitterShare 'SMC Update - October 2013' on LinkedInShare 'SMC Update - October 2013' on reddit


No Comments to “SMC Update - October 2013”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.